As of June 14, 2025, MorphoSys AG (MOR.DE) reports a ROE (Return on Equity) of -386.82%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of MorphoSys AG's ROE (Return on Equity)
Over recent years, MorphoSys AG's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2023-12-31 | -386.82% |
| 2022-12-31 | -95.97% |
| 2021-12-31 | -210.09% |
| 2020-12-31 | 15.76% |
| 2019-12-31 | -26.10% |
This slight downward trend highlights how MorphoSys AG manages its efficiency in generating profits from shareholders' equity over time.
Comparing MorphoSys AG's ROE (Return on Equity) to Peers
To better understand MorphoSys AG's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| MorphoSys AG (MOR.DE) | -386.82% |
| Inventiva SA (IVA.PA) | 172.73% |
| Hansa Biopharma AB (HNSA.ST) | 136.86% |
| Nanobiotix SA (NANO.PA) | 103.70% |
| Basilea Pharmaceutica AG Allschwil (BSLN.SW) | 95.80% |
| Vaccibody AS (VACC.OL) | 83.74% |
Compared to its competitors, MorphoSys AG's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.